Please use this identifier to cite or link to this item: https://doi.org/10.1177/0091270009332813
DC FieldValue
dc.titleMechanism-Based Enterohepatic Circulation Model of Mycophenolic Acid and Its Glucuronide Metabolite: Assessment of Impact of Cyclosporine Dose in Asian Renal Transplant Patients
dc.contributor.authorYau, Wai-Ping
dc.contributor.authorVathsala, Anantharaman
dc.contributor.authorLou, Huei-Xin
dc.contributor.authorZhou, Shufeng
dc.contributor.authorChan, Eli
dc.date.accessioned2022-07-29T07:04:14Z
dc.date.available2022-07-29T07:04:14Z
dc.date.issued2009-06-01
dc.identifier.citationYau, Wai-Ping, Vathsala, Anantharaman, Lou, Huei-Xin, Zhou, Shufeng, Chan, Eli (2009-06-01). Mechanism-Based Enterohepatic Circulation Model of Mycophenolic Acid and Its Glucuronide Metabolite: Assessment of Impact of Cyclosporine Dose in Asian Renal Transplant Patients. JOURNAL OF CLINICAL PHARMACOLOGY 49 (6) : 684-699. ScholarBank@NUS Repository. https://doi.org/10.1177/0091270009332813
dc.identifier.issn0091-2700
dc.identifier.issn1552-4604
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/229442
dc.description.abstractMycophenolic acid (MPA) is mainly metabolized to MPA-glucuronide (MPAG), which may be reconverted to MPA following enterohepatic circulation (EHC). A physiologically realistic EHC model was proposed to estimate and assess the impact of cyclosporine (CsA) dose on the extent of EHC of MPA and MPAG. After the first oral dose of mycophenolate mofetil (MMF), theMPA and MPAG plasma concentration-time data of 14 adult renal transplant patients (12 receiving concomitant CsA and prednisolone and 2 receiving only concomitant prednisolone without CsA) were analyzed by individual pharmacokinetic modeling using a proposed 5-compartment drug and metabolite EHC model with a time-varying gallbladder emptying process. Simulations were performed to assess the influence of the time of bile release after dosing (T bile) and the gallbladder emptying interval (τ gall) on the EHC process. The extent of EHC for both MPA and MPAG tended to be lower in the group receiving CsA coadministration and decreased with increasing total body weight-adjusted CsA dose. Simulations revealed that T bjle and τ gall influenced the time of occurrence and maximum concentration of the second peak, as well as the extent of EHC, for MPA and MPAG. © 2009 the American College of Clinical Pharmacology.
dc.language.isoen
dc.publisherWILEY
dc.sourceElements
dc.subjectScience & Technology
dc.subjectLife Sciences & Biomedicine
dc.subjectPharmacology & Pharmacy
dc.subjectMycophenolic acid
dc.subjectpharmacokinetic modeling
dc.subjectenterohepatic circulation
dc.subjectrenal transplant
dc.subjectcyclosporine
dc.subjectPOPULATION PHARMACOKINETIC ANALYSIS
dc.subjectRESISTANCE-ASSOCIATED PROTEIN-2
dc.subjectRANDOMIZED-TRIAL
dc.subjectACUTE REJECTION
dc.subjectMOFETIL
dc.subjectRECIPIENTS
dc.subjectTACROLIMUS
dc.subjectPREVENTION
dc.subjectKIDNEY
dc.subjectCOMBINATION
dc.typeArticle
dc.date.updated2022-07-23T13:07:03Z
dc.contributor.departmentDEPT OF PHARMACY
dc.contributor.departmentMEDICINE
dc.contributor.departmentPHARMACY
dc.description.doi10.1177/0091270009332813
dc.description.sourcetitleJOURNAL OF CLINICAL PHARMACOLOGY
dc.description.volume49
dc.description.issue6
dc.description.page684-699
dc.description.placeUnited States
dc.published.statePublished
Appears in Collections:Staff Publications
Elements

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
Mechanism-based EHC model of MPA MPAG (JCP).pdf1.03 MBAdobe PDF

CLOSED

Published

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.